Type 2 diabetes is generally associated with low levels of physical activity and high levels of sedentary behavior (1–4). However, it is possible for physically active individuals to develop type 2 diabetes, and, once diagnosed, many people wish to adopt regular exercise routines (5–7).
Glucagon-like peptide 1 (GLP-1) receptor agonists comprise one of several medication classes available to treat type 2 diabetes. GLP-1 receptor agonists are a preferred treatment option for many different individuals with type 2 diabetes (1).